Jennifer Lachey - 13 Dec 2021 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Scientific Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
13 Dec 2021
Net transactions value
-$132,763
Form type
4
Filing time
15 Dec 2021, 15:48:41 UTC
Previous filing
12 Nov 2021
Next filing
07 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $574 +1,915 +2.2% $0.3000* 87,615 13 Dec 2021 Direct
transaction KROS Common Stock Sale $76,067 -1,518 -1.7% $50.11 86,097 13 Dec 2021 Direct F1, F2
transaction KROS Common Stock Sale $20,366 -390 -0.45% $52.22 85,707 13 Dec 2021 Direct F1, F3
transaction KROS Common Stock Sale $375 -7 -0.01% $53.64 85,700 13 Dec 2021 Direct F1
transaction KROS Common Stock Options Exercise $220 +735 +0.86% $0.3000* 86,435 15 Dec 2021 Direct
transaction KROS Common Stock Sale $36,750 -735 -0.85% $50.00 85,700 15 Dec 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -1,915 -2% $0.000000 95,990 13 Dec 2021 Common Stock 1,915 $0.3000 Direct F4
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -735 -0.77% $0.000000 95,255 15 Dec 2021 Common Stock 735 $0.3000 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.495 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.06 to $52.86 inclusive.
F4 Immediately exercisable.